Physician profile
Melinda Cusack
NPI 1932580909
$752.51
in general payments reported to CMS, 2019-2025
13 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.27 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.53 |
| Education | $247.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $361.88 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $114.76 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.98 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $34.44 | 2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.08 | 2025 | Caplyta |
| Novo Nordisk INC | $30.62 | 2025 | Ozempic, Wegovy, Saxenda |
| Teva Pharmaceuticals USA, INC. | $24.01 | 2025 | Austedo Xr |
| Aimmune Therapeutics, INC. | $19.81 | 2025 | Zenpep |
| Neurocrine Biosciences, INC. | $17.18 | 2025 | |
| Lilly USA, LLC | $16.68 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $16.62 | 2025 | The Cologuard Plus Collection Kit |
| Abbvie INC. | $16.27 | 2023 | Vraylar |
| Organon LLC | $13.18 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Cusack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.